Jun 23, 2025, 12:40
A New Era in Hemophilia A Prophylaxis: Dr. Shima Presented Groundbreaking Phase I/II Results for NXT007
NXT007 Hemophilia A Prophylaxis took center stage today when Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on X.
“A New Era in Haemophilia A Prophylaxis. Dr. Shima presented groundbreaking phase I/II results for NXT007, a next-generation bispecific antibody: 30 patients with severe haemophilia A (no inhibitors), age range: 12-65 years (median age 39.5 years), subcutaneous dosing: 0.072-1.08 mg/kg every 4 weeks.
Higher dose cohorts (B-3, B-4) achieved FVIII-equivalent activity in the normal range.
Well-tolerated profile with no thromboembolic events, but high anti-drug antibody prevalence: 22/30 patients (73%) and effect on plasma concentrations in 2/22.”
Stay up to date with Hemostasis Today
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications
-
Jan 6, 2026, 09:52Antoine Francis: Plasma is Not Just Another Component of Healthcare…
-
Jan 6, 2026, 09:45Hurry to Join EHC Youth Leadership Workshop 2026
-
Jan 6, 2026, 09:41Andrew Petrosoniak Makes It to N1 on EMCases Best of 2025!
-
Jan 6, 2026, 09:35Sara Ng: Moving Beyond Management to Stewardship – “Advancing Anticoagulation Stewardship” Released by NQF
-
Jan 6, 2026, 09:30Wolfgang Miesbach: Excellent 4-Year Data of Etranacogene Dezaparvovec in Haemophilia B
-
Jan 6, 2026, 09:09Abdulrahman Nasiri: A New Perspective on Avatrombopag in Aplastic Anemia